Online inquiry

IVTScrip™ mRNA-Anti-PDGFRA, 3G3(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ447MR)

This product GTTS-WQ447MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets PDGFRA gene. The antibody can be applied in Ovarian Cancer research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001347829.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5156
UniProt ID P16234
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDGFRA, 3G3(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ447MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ7240MR IVTScrip™ mRNA-Anti-STAB1, FP-1302(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA FP-1302
GTTS-WQ2929MR IVTScrip™ mRNA-Anti-ERBB3, AMG888(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA AMG888
GTTS-WQ14920MR IVTScrip™ mRNA-Anti-stx2 A-subunit, Shigamabs®(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA Shigamabs®
GTTS-WQ3916MR IVTScrip™ mRNA-Anti-CD274, BCD-135(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BCD-135
GTTS-WQ8660MR IVTScrip™ mRNA-Anti-CD38, HuMax-CD38(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA HuMax-CD38
GTTS-WQ3941MR IVTScrip™ mRNA-Anti-CTLA4, BCD-145(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BCD-145
GTTS-WQ13815MR IVTScrip™ mRNA-Anti-S, REGN-10987(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-10987
GTTS-WQ9567MR IVTScrip™ mRNA-Anti-EGFR&MET, JNJ-61186372(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA JNJ-61186372
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW